Search hospitals
>
Nebraska
>
Omaha
Creighton University Medical Center
Claim this profile
Omaha, Nebraska 68131
Global Leader in Cancer
Global Leader in Breast Cancer
Conducts research for Lung Cancer
Conducts research for Breast cancer
Conducts research for Prostate Cancer
368 reported clinical trials
3 medical researchers
Summary
Creighton University Medical Center is a medical facility located in Omaha, Nebraska. This center is recognized for care of Cancer, Breast Cancer, Lung Cancer, Breast cancer, Prostate Cancer and other specialties. Creighton University Medical Center is involved with conducting 368 clinical trials across 496 conditions. There are 3 research doctors associated with this hospital, such as Richard L. Deming, Shahzad Siddique, and Mehmet S. Copur.
Area of expertise
Cancer
Creighton University Medical Center has run 90 trials for Cancer. Some of their research focus areas include:
Breast Cancer
Creighton University Medical Center has run 69 trials for Breast Cancer. Some of their research focus areas include:
Top PIs
Richard L. Deming
Mercy Medical Center - Des Moines
7 years of reported clinical research
Shahzad Siddique
Penrose-Saint Francis Healthcare
3 years of reported clinical research
Mehmet S. Copur
Bethesda North Hospital
13 years of reported clinical research
Clinical Trials running at Creighton University Medical Center
Lung Cancer
Bladder Cancer
Prostate Cancer
Cancer
Breast cancer
Ovarian Cancer
Multiple Myeloma
Bladder Carcinoma
Breast Cancer
Esophageal cancer
Treatment Timing
for Non-Small Cell Lung Cancer
This phase III trial compares standard therapy given after surgery (adjuvant) to standard therapy given before and after surgery (perioperative) in treating patients with stage II-IIIB non-small cell lung cancer (NSCLC) that can be removed by surgery (resectable). The usual approach for patients with resectable NSCLC is chemotherapy and/or immunotherapy before surgery, after surgery, or both before and after surgery. This study is being done to find out which approach is better at treating patients with lung cancer. Treatment will be administered according to the current standard of care at the time of enrollment. Chemotherapy options may include cisplatin, carboplatin, pemetrexed, gemcitabine, docetaxel, and vinorelbine at standard doses according to the treating physician. Cisplatin is in a class of medications known as platinum-containing compounds. It works by killing, stopping or slowing the growth of tumor cells. Carboplatin is in a class of medications known as platinum-containing compounds. It works in a way similar to the anticancer drug cisplatin, but may be better tolerated than cisplatin. Carboplatin works by killing, stopping or slowing the growth of tumor cells. Pemetrexed is in a class of medications called antifolate antineoplastic agents. It works by stopping cells from using folic acid to make deoxyribonucleic acid (DNA) and may kill tumor cells. Gemcitabine is a chemotherapy drug that blocks the cells from making DNA and may kill tumor cells. Docetaxel is in a class of medications called taxanes. It stops tumor cells from growing and dividing and may kill them. Other chemotherapy drugs, such as vinorelbine, work in different ways to stop the growth of tumor cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading . Immunotherapy with monoclonal antibodies, such as nivolumab, pembrolizumab, and atezolizumab, may help the body's immune system attack the tumor, and may interfere with the ability of tumor cells to grow and spread. Starting treatment with chemotherapy and immunotherapy prior to surgery and continuing treatment after surgery may be a more effective treatment option than adjuvant therapy alone in patients with stage II-IIIB resectable NSCLC.
Recruiting
2 awards
Phase 3
4 criteria
Osimertinib + Bevacizumab
for Lung Cancer
This phase III trial compares the effect of bevacizumab and osimertinib combination vs. osimertinib alone for the treatment of non-small cell lung cancer that has spread outside of the lungs (stage IIIB-IV) and has a change (mutation) in a gene called EGFR. The EGFR protein is involved in cell signaling pathways that control cell division and survival. Sometimes, mutations in the EGFR gene cause EGFR proteins to be made in higher than normal amounts on some types of cancer cells. This causes cancer cells to divide more rapidly. Osimertinib may stop the growth of tumor cells by blocking EGFR that is needed for cell growth in this type of cancer. Bevacizumab is in a class of medications called antiangiogenic agents. It works by stopping the formation of blood vessels that bring oxygen and nutrients to tumor. This may slow the growth and spread of tumor. Giving osimertinib with bevacizumab may control cancer for longer and help patients live longer as compared to osimertinib alone.
Recruiting
2 awards
Phase 3
31 criteria
Immunotherapy + Chemotherapy
for Non-Small Cell Lung Cancer
This phase III ALCHEMIST treatment trial tests the addition of pembrolizumab to usual chemotherapy for the treatment of stage IIA, IIB, IIIA or IIIB non-small cell lung cancer that has been removed by surgery. Immunotherapy with monoclonal antibodies, such as pembrolizumab, may help the body's immune system attack the cancer, and may interfere with the ability of tumor cells to grow and spread. Chemotherapy drugs, such as cisplatin, pemetrexed, carboplatin, gemcitabine hydrochloride, and paclitaxel, work in different ways to stop the growth of tumor cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. Giving pembrolizumab with usual chemotherapy may help increase survival times in patients with stage IIA, IIB, IIIA or IIIB non-small cell lung cancer.
Recruiting
2 awards
Phase 3
27 criteria
Similar Hospitals nearby
Select from list below to view details
Frequently asked questions
What kind of research happens at Creighton University Medical Center?
Creighton University Medical Center is a medical facility located in Omaha, Nebraska. This center is recognized for care of Cancer, Breast Cancer, Lung Cancer, Breast cancer, Prostate Cancer and other specialties. Creighton University Medical Center is involved with conducting 368 clinical trials across 496 conditions. There are 3 research doctors associated with this hospital, such as Richard L. Deming, Shahzad Siddique, and Mehmet S. Copur.
Where is Creighton University Medical Center located?
To reach Creighton University Medical Center in Omaha, NE, take I-680 to exit 4 for Mercy Road, then head north for about a mile to the hospital located at 7500 Mercy Rd.
Who should I call to ask about financial aid or insurance network?
**Creighton University Medical Center Financial Assistance:** - **Contact Information:** For financial assistance, reach out to the Financial Aid Office via email at finaid@creighton.edu or call 800.282.5835 / 402.280.2731. They assist with undergraduate, graduate, or professional school financial inquiries. For specific staff contacts, visit the Creighton University website. **Insurance-Related Inquiries:** - **Contact Information:** For insurance questions, waivers, or enrollment in the University-sponsored Student Health Insurance Plan, contact the Student Health Education and Compliance Office at studentinsurance@creighton.edu or call 402.280.2735.
What insurance does Creighton University Medical Center accept?
The Creighton University Medical Center accepts UnitedHealthcare Student Resources and UnitedHealthcare medical coverage. Students can benefit from the university-sponsored Student Health Insurance Plan, offering comprehensive medical and mental health care. Employees have three plan options: Creighton Consumer Account Plan (CCAP), PPO1, and PPO2, with pharmacy benefits by Express Scripts, dental by MetLife, and vision by Vision Service Plan (VSP).
What awards or recognition has Creighton University Medical Center received?
Creighton University Medical Center, located in Omaha, Nebraska, is celebrated for its high-quality care, as recognized by U.S. News. The university's Division of Clinical Research enhances clinical studies by assisting in various stages including IRB submission and study management. Its research excellence spans cancer, antibiotic development, diabetes, and hearing, with significant accomplishments in hereditary and skin cancer, breast and prostate cancer, and hearing loss prevention.
Unbiased Results
We believe in providing patients with all the options.
Your Data Stays Your Data
We only share your information with the clinical trials you're trying to access.
Verified Trials Only
All of our trials are run by licensed doctors, researchers, and healthcare companies.
Unbiased Results
We believe in providing patients with all the options.
Your Data Stays Your Data
We only share your information with the clinical trials you're trying to access.
Verified Trials Only
All of our trials are run by licensed doctors, researchers, and healthcare companies.